- These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year -
- Allergan plans US NDA submission in second half of 2019 -
PR Newswire
DUBLIN, Jan. 7, 2019
PR Newswire
DUBLIN, Jan. 7, 2019
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey